TEL-AVIV, Israel, Dec. 20, 2016 (GLOBE NEWSWIRE) --
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the
“Company”), a biopharmaceutical company primarily focused on development
and commercialization of late clinical-stage, proprietary,
orally-administered, small molecule drugs for gastrointestinal and
inflammatory diseases and cancer, today announced that the first
patients have been screened and a first patient has been dosed in the
Phase Ib/II clinical study evaluating YELIVA® (ABC294640) in patients with refractory or relapsed multiple myeloma.
The
open-label, dose escalation Phase Ib/II study is being conducted at
Duke University Medical Center and is expected to enroll up to 77
patients with refractory or relapsed multiple myeloma who have
previously been treated with proteasome inhibitors and immunomodulatory
drugs.
No comments:
Post a Comment